If you could vote on Brexit now which option would you choose?
   

Merck's Covid Antiviral Gets WHO Backing for High-Risk Patients


Merck & Co.’s Covid-19 antiviral pill was endorsed by a World Health Organization panel for patients in the early stages of disease who face high risk of hospitalization. The WHO panel of international experts, which looked at data from six randomized clinical trials involving more than 4,000 patients, found a moderate certainty that Merck’s molnupiravir reduces the risk of hospital admission and recovery time. The effect on mortality wasn’t so clear. The decision was published Thursday in the BMJ medical journal. Merck’s pill is used in the U.S. and U.K. to treat Covid patients at high risk of severe illness, but its mechanism of action and lesser efficacy have prompted a shift toward Pfizer Inc.’s Paxlovid and other drugs. U.S. National Institutes of Health guidelines specify that molnupiravir should be used only when other medications for outpatients can’t be given.

Bloomberg - March 2, 2022

View the full story here: https://www.bloomberg.com/news/articles/2022-03-02/merck-s-covid-antiviral-gets-who-backing-for-high-risk-patients